S-1 Executive Committee

City National Bank Announces New CEO

Retrieved on: 
Friday, November 10, 2023
Fifth Third Bank, Entertainment, Risk management, City, Executive Committee, Head, Retail banking, Culture, Rest, City National Bank (California), S-1 Executive Committee, Management, Interior design, Online shopping

Hammond brings to City National more than 30 years of financial services experience, including 15 years in leadership positions at Fifth Third Bancorp, a large commercial bank and the ninth largest U.S.-based consumer bank.

Key Points: 
  • Hammond brings to City National more than 30 years of financial services experience, including 15 years in leadership positions at Fifth Third Bancorp, a large commercial bank and the ninth largest U.S.-based consumer bank.
  • “I look forward to working closely with Greg, Kelly and the rest of the leadership team to build on the strength of City National and lead the business into the future.”
    Carmichael, executive chair of City National, said: “Howard brings exceptionally strong experience to City National.
  • He is the ideal leader to take City National to its next stage and prepare the bank for future success.”
    Coffey will assume the newly created role of CEO, City National Entertainment, enabling her to further add to City National’s strength in delivering strategic advice and a premier client experience.
  • I’m excited about the opportunity to work more closely with clients and help City National serve them even better.”
    Carmichael said: “Kelly has had a tremendous impact on City National over the last five years.

Molson Coors Nominates Jill Timm as an Independent Director to Join Its Board of Directors

Retrieved on: 
Friday, December 15, 2023
Retail, Food, Beverage, Wine & Spirits, NYSE, Harvard Business School, Woman, Executive Committee, CFO, Treasury, Coors, Timm, Bachelor of Business Administration, Molson Brewery, Business administration, Molson Coors, National bank, Vachon, University, Retirement, Growth, S-1 Executive Committee, University of Wisconsin–Whitewater, National Bank of Canada, TSX, Management, Beer

The Molson Coors Beverage Company (NYSE: TAP, TAP.A; TSX: TPX.B, TPX.A) Board of Directors announced today that Jill Timm has been nominated as an independent director effective December 16, 2023.

Key Points: 
  • The Molson Coors Beverage Company (NYSE: TAP, TAP.A; TSX: TPX.B, TPX.A) Board of Directors announced today that Jill Timm has been nominated as an independent director effective December 16, 2023.
  • The board also announced the retirement of Director Louis Vachon, who has served on the Molson Coors Board of Directors since 2012.
  • “We couldn’t be more pleased to nominate Jill for election to our board,” said Geoffrey Molson, chair of the Molson Coors Board of Directors.
  • Vachon, the former president and CEO of the National Bank of Canada, has served on the Molson Coors Board of Directors since 2012.

Bayer and CrossBay Medical to develop novel Intrauterine System Inserter

Retrieved on: 
Thursday, November 30, 2023
Medical Supplies, Biotechnology, Health, Women, Pharmaceutical, Medical Devices, Health Insurance, Research, Fitness & Nutrition, Consumer, Science, Woman, Business development, IUS, Executive Committee, Multimedia, Birth, Partnership, S-1 Executive Committee, Pharmaceutical industry, Birth control, Bayer

Bayer and CrossBay Medical Inc., today announced a development and option to license agreement that will allow the development and production of a single-handed inserter to be combined with Bayer’s leading hormonal IUS portfolio.

Key Points: 
  • Bayer and CrossBay Medical Inc., today announced a development and option to license agreement that will allow the development and production of a single-handed inserter to be combined with Bayer’s leading hormonal IUS portfolio.
  • View the full release here: https://www.businesswire.com/news/home/20231130816843/en/
    The partnership will result in the further development and expansion of CrossBay’s existing innovative CrossGlide™ technology.
  • The CrossGlide technology has the potential to substantially improve the intrauterine placement experience by limiting and reducing the discomfort some women may experience during IUS insertion.
  • By removing these steps, the inserter also has the potential to reduce procedure time necessary for healthcare professionals.

Calvin Butler and Jeff Edwards Elected to Battelle Board of Directors

Retrieved on: 
Wednesday, November 29, 2023
Technology, Manufacturing, Construction & Property, Other Energy, Other Science, Other Technology, Research, Other Manufacturing, Energy, Science, Other Construction & Property, Columbus Museum of Art, Institute of International Education, Argonne National Laboratory, Delmarva Power, Builders hardware, Construction, Climate change, BGE, STEM, Executive Committee, Infrastructure, Exelon, Investment, Bradley University, History, School, Columbus Foundation, Miami University, Devotion (Anberlin album), Commonwealth Edison, Health, Trustee, Housing, Environment, Retirement, S-1 Executive Committee, PECO, Columbus School of Law, Congress, Government, Pepco, Columbus Museum, IIE, Management, Art

Battelle announced today the election of two distinguished industry leaders to its Board of Directors.

Key Points: 
  • Battelle announced today the election of two distinguished industry leaders to its Board of Directors.
  • Calvin Butler is President and CEO of Exelon Corp. overseeing Exelon’s six local electric and natural gas companies—Atlantic City Electric, BGE, ComEd, Delmarva Power, PECO and Pepco.
  • Battelle Board Chairman Kirkland Donald said, “The role of the Board of Directors is to bring perspectives from a wide variety of experiences to benefit Battelle’s long-term success.
  • “Jeff is an outstanding addition to our Board of Directors,” said Battelle President and CEO Lou Von Thaer.

Former MOPSC Commission Chairman Kevin Gunn to join Evergy

Retrieved on: 
Tuesday, November 28, 2023
Sustainability, Energy, Utilities, Environment, NextEra Energy Resources, Policy, Executive Committee, Missouri Public Service Commission, State, Greater St. Louis, National Association, EVRG, Bar association, NARUC, Partnership, Illinois Commerce Commission, Political Affairs (magazine), S-1 Executive Committee, Renewable energy, Evergy

Evergy, Inc. (NASDAQ: EVRG) announced today that Kevin Gunn will join its leadership team in January.

Key Points: 
  • Evergy, Inc. (NASDAQ: EVRG) announced today that Kevin Gunn will join its leadership team in January.
  • I’m excited to have him join our Evergy leadership team.”
    Gunn joins Evergy with 20 years of experience in policymaking, energy and regulation.
  • He served on the Missouri Public Service Commission for five years, including as Chairman, and on the board of the National Association of Regulatory Utility Commissioners (NARUC).
  • In his role at Evergy, Gunn will focus in particular on the company’s work with Missouri and federal regulators and stakeholders.

Point B Appoints New C-Level Executives to Accelerate Growth and Transformation

Retrieved on: 
Monday, November 20, 2023
Technology, Consulting, Professional Services, Other Technology, Operating model, Growth, S-1 Executive Committee, Operation, NPS, Executive Committee, Management

Point B , a consulting firm that drives impact by working at the intersection of expertise, industry insight, and transformative technology, has announced the appointment of several key executives to leadership roles to accelerate growth, streamline operations, and deepen the company’s technology expertise.

Key Points: 
  • Point B , a consulting firm that drives impact by working at the intersection of expertise, industry insight, and transformative technology, has announced the appointment of several key executives to leadership roles to accelerate growth, streamline operations, and deepen the company’s technology expertise.
  • The executives in these roles will help Point B transform to serve the needs of our customers better,” says Point B President & CEO Brian Turner .
  • “Point B is known for bringing trusted talent to each customer engagement.
  • The company’s transformation includes a keen focus on the role technology plays in helping companies evolve and stay competitive.

Greenidge Announces Leadership Transition

Retrieved on: 
Thursday, November 16, 2023
Professional Services, Data Management, Data Analytics, Technology, Cryptocurrency, Web3, Artificial Intelligence, Senior, Organization, Executive Committee, Trinity College, HKL, Natural gas, S-1 Executive Committee, Growth, AI, Management, Atlas

Greenidge Generation Holdings Inc. (NASDAQ: GREE) (“Greenidge” or the “Company”), a vertically integrated cryptocurrency datacenter and power generation company, today announced that Jordan Kovler has been appointed to replace David Anderson as Greenidge’s Chief Executive Officer.

Key Points: 
  • Greenidge Generation Holdings Inc. (NASDAQ: GREE) (“Greenidge” or the “Company”), a vertically integrated cryptocurrency datacenter and power generation company, today announced that Jordan Kovler has been appointed to replace David Anderson as Greenidge’s Chief Executive Officer.
  • All of the executive transitions, which have been approved by the Board, are effective as of November 16, 2023.
  • His differentiated experience and ability to build Web3 organizations using innovative approaches make him well-suited to lead Greenidge as our industry continues to evolve.
  • I look forward to working with Jordan in my new role as Chairman and am confident that he will position Greenidge for future growth while focusing on driving shareholder value.”
    “I am excited for the opportunity to lead Greenidge during this next phase of our lifecycle.

Bayer and Recursion focus research collaboration on Oncology

Retrieved on: 
Thursday, November 9, 2023
Technology, Research, Clinical Trials, Biotechnology, Health, Pharmaceutical, Science, Artificial Intelligence, Oncology, Recursion, Artificial intelligence, Chemistry, Business development, Executive Committee, Data, Patient, Multimedia, USD, Therapy, Drug discovery, Cancer, S-1 Executive Committee, Bias, Biology, Pharmaceutical industry, Medical device, Bayer

Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to precision oncology.

Key Points: 
  • Bayer and US-based Recursion Pharmaceuticals, Inc., a clinical stage TechBio company decoding biology to industrialize drug discovery, today announced that they have updated the focus of their research collaboration to precision oncology.
  • This strategic shift will enable Bayer to utilize Recursion’s capabilities to initiate and advance the identification of novel therapeutic targets for challenging oncology indications with high unmet need.
  • “Every cancer is different and requires an individual approach,” said Dominik Ruettinger, M.D., Ph.D., Global Head of Research and Early Development for Oncology, Pharmaceuticals Division, Bayer AG.
  • Leaps by Bayer, the impact investment arm of Bayer AG, led Recursion’s Series D financing in 2020 with an investment of USD 50 million.

AMGEN ANNOUNCES EXECUTIVE APPOINTMENTS TO ACCELERATE INNOVATION

Retrieved on: 
Thursday, December 14, 2023
Bradner, Ohio, Executive Committee, Investment, Biotechnology, Patient, Research and development, Culture, Biomedical Research, Drug discovery, Harvard Medical School, Development, R, S-1 Executive Committee, Dana–Farber Cancer Institute, AI, Amgen, Inflammation, AMGN, Management, Fine chemical, Research, Novartis

THOUSAND OAKS, Calif., Dec. 14, 2023 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced two changes to its senior leadership team in the areas of research and development (R&D) and technology, underscoring the advancement of the company's robust pipeline and its commitment to ongoing scientific and technological innovation. James Bradner, M.D., has joined Amgen as executive vice president of Research and Development, and chief scientific officer. Bradner is succeeding David M. Reese, M.D., who has been appointed executive vice president and chief technology officer. Both Bradner and Reese will report to Robert A. Bradway, chairman and chief executive officer at Amgen.

Key Points: 
  • James Bradner, M.D., has joined Amgen as executive vice president of Research and Development, and chief scientific officer.
  • Both Bradner and Reese will report to Robert A. Bradway, chairman and chief executive officer at Amgen.
  • "For more than 40 years, Amgen's focus on innovation has enabled us to deliver life-changing medicines to patients suffering from serious diseases around the world," said Robert A. Bradway, chairman and chief executive officer at Amgen.
  • At Amgen we have been preparing for this moment for over a decade," said David M. Reese, executive vice president and chief technology officer at Amgen.

Secura Bio Announces the Addition of Two New Board of Directors Members

Retrieved on: 
Thursday, December 7, 2023
Bayer, Executive Committee, Commercial, Hematology, Patient, Seagen, Standard of care, MD, S-1 Executive Committee, Dermatology, Genentech, Leo Pharma, Management

SUMMERLIN, Nev., Dec. 7, 2023 /PRNewswire/ -- Secura Bio, Inc. (Secura Bio) - ( www.securabio.com ), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, today announces that it has added two members to the board of directors of Secura Bio Holdings, Inc.

Key Points: 
  • SUMMERLIN, Nev., Dec. 7, 2023 /PRNewswire/ -- Secura Bio, Inc. (Secura Bio) - ( www.securabio.com ), an integrated pharmaceutical company dedicated to the worldwide development and commercialization of impactful oncology therapies, today announces that it has added two members to the board of directors of Secura Bio Holdings, Inc.
  • The new members are Joerg Moeller, MD and Charles (Chip) R. Romp.
  • He was the former Head of Global Research and Development at Bayer Pharmaceuticals and a member of Bayer Pharma´s Executive Committee.
  • With his addition to the board, Chip Romp stated, "I am thrilled to join the board of directors and look forward to working with the company's leadership to improve the lives of patients".